Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis

Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis

  1. 1.   Antonio Isidoro1,
  2. 2.   Enrique Casado2,
  3. 3.   Andrés Redondo2,
  4. 4.   Paloma Acebo1,
  5. 5.   Enrique Espinosa2,
  6. 6.   Andrés M. Alonso4,
  7. 7.   Paloma Cejas2,
  8. 8.   David Hardisson3,
  9. 9.   Juan A. Fresno Vara2,

10. Cristobal Belda-Iniesta2,

11. Manuel González-Barón2 and

12. José M. Cuezva1,*

+ Author Affiliations

1.   1Departamento de Biología Molecular, Centro de Biología Molecular “Severo Ochoa”, Universidad Autónoma de Madrid, 28049 Madrid, Spain, 2Servicio de Oncología Médica and 3Servicio de Anatomía Patológica, Hospital Universitario La Paz, Universidad Autónoma de Madrid, 28046 Madrid, Spain and 4Departamento de Estadística, Facultad de Ciencias Sociales y Jurídicas, Universidad Carlos III de Madrid, Getafe, 28903 Madrid, Spain
  1. *To whom correspondence should be addressed. Tel: +34 91 497 4866; Fax: +34 91 497 4799; Email: jmcuezva@cbm.uam.es

     Received May 4, 2005.

     Accepted July 15, 2005.

     Revision received July 13, 2005.

Abstract

The aim of this study was to investigate selected proteomic markers of the metabolic phenotype of breast carcinomas as prognostic markers of cancer progression. For this purpose, a series of 101 breast carcinomas and 13 uninvolved breast samples were examined for quantitative differences in protein expression of mitochondrial and glycolytic markers. The β-subunit of the mitochondrial H+-ATP synthase (β-F1-ATPase) and heat shock protein 60 (Hsp60), and the glycolytic glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase and lactate dehydrogenase were identified by immunological techniques. Correlations of the expression level of the protein markers and of the ratios derived from them were established with the clinicopathological information of the tumors and the follow-up data of the patients. The metabolic proteome of breast cancer specimens revealed a pronounced shift towards an enhanced glycolytic phenotype concurrent with a profound alteration on the mitochondrial β-F1-ATPase/Hsp60 ratio when compared with normal samples. Discriminant analysis using markers of the metabolic signature as predictor variables revealed a classification sensitivity of ∼97%. Kaplan–Meier survival analysis showed that several of the proteomic variables significantly correlated with overall and disease-free survival of the patients. The expression level of β-F1-ATPase per se allowed the identification of a subgroup of breast cancer patients with significantly worse prognosis. Multivariate Cox regression analysis indicated that tumor expression of β-F1-ATPase is a significant marker independent from clinical variables to assess the prognosis of the patients. We conclude that the alteration of the mitochondrial and glycolytic proteomes is a hallmark feature of breast cancer further providing relevant markers to aid in the prognosis of breast cancer patients.

 

2 thoughts on “Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis

  1. Pretty great post. I simply stumbled upon your weblog and wished to say that I have really loved browsing your blog posts. In any case I’ll be subscribing in your rss feed and I am hoping you write once more very soon!

  2. Thank you so much for following me. I really appreciate your comments and you are welcome to post any thoughts on my blog anytime. Your positive feedback is most welcomed!
    Thanks!
    Susan Zager

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>